NN2211: A long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs

European Journal of Pharmacology

Volumn 451, Issue 2, 2002, Pages 217-225

  Ribel, Ulla ^a   Larsen, Marianne O ^a   Rolin, Bidda ^a   Carr, Richard D ^a   Wilken, Michael ^a   Sturis, Jeppe ^a   Westergaard, Lisbet ^a   Deacon, Carolyn F ^b   Knudsen, Lotte Bjerre ^a  

^a NOVO NORDISK A S   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Diabetes type 2, Glucose tolerance; Gastric emptying; GLP 1 glucagon like peptide 1 derivative; Glucagon; Insulin sensitivity; Minipig

Indexed keywords

ANTIDIABETIC AGENT; FRUCTOSAMINE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1[7-37][34 ARGININE 26 LYSINE [N EPSILON [GAMMA GLUTAMINE(N ALPHA HEXADECANOYL)]]]; GLUCOSE; INSULIN; LIRAGLUTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; FRUCTOSAMINE BLOOD LEVEL; GLUCAGON BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INTOLERANCE; GLUCOSE UTILIZATION; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; MALE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RISK; STOMACH EMPTYING; SWINE;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE INTOLERANCE; HYPOGLYCEMIC AGENTS; INSULIN; MALE; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; SWINE, MINIATURE;

EID: 0037072573     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02189-1     Document Type: Article

References (43)

1. Buteau J., Roduit R., Susini S., Prentki M. GLP-1 promotes DNA synthesis, activates phosphatidylinositol-3-kinase and increases transcription factor pancreatic and duodenal homebox gene 1 (PDX-1) DNA binding activity in beta (INS-1) cells. Diabetologia. 42:1999;856-864.
2. D'Alessio D.A., Kahn S.E., Leusner C.R., Ensinck J.W. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J. Clin. Invest. 93:1994;2263-2266.
3. D'Alessio D.A., Prigeon R.L., Ensinck J.W. Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes. A physiological role of glucagon-like peptide I. Diabetes. 44:1995;1433-1437.
4. Deacon C.F., Johnsen A.H., Holst J.J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide which is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 80:1995;952-957.
5. Deacon C.F., Pridal L., Klarskov L., Olesen M., Holst J.J. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in anesthetized pig. Am. J. Physiol. 271:1996;E458-E464.
6. Deacon C.F., Knudsen L.B., Madsen K., Wiberg F.C., Jacobsen O., Holst J.J. Dipeptidyl peptidase IV resistant analogues of GLP-1 which have extended metabolic stability and improved biological activity. Diabetologia. 41:1998;271-278.
7. Edvell A., Lindström P. Initiation of increased pancreatic islet growth in young normoglycaemic mice (Umeå +/?). Endocrinology. 140:1999;778-783.
8. Edwards C.M., Stanley S.A., Davis R., Brynes A.E., Frost G.S., Seal L.J., Ghatei M.A., Bloom S.R. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am. J. Physiol. 281:2001;E155-E161.
9. Flint A., Raben A., Astrup A., Holst J.J. GLP-1 promotes satiety and suppress energy intake in humans. J. Clin. Invest. 101:1998;515-520.
10. Gang X., Stoffers D.A., Habener J.F., Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 48:1999;2270-2276.
11. Greig N.H., Holloway H.N., DeOre K.A., Jani D., Wang Y., Zhou J., Garant M.J., Egan J.M. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia. 42:1999;45-50.
12. Gromada J., Holst J.J., Rorsman P. Cellular regulation of islet hormone secretion by the incretin hormone GLP-1. Pflugers Arch. Eur. J. Phys. 435:1998;583-594.
13. Gutniak M.K., Linde B., Holst J.J., Efendic S. Subcutaneous injection of the incretin hormone GLP-1 abolishes postprandial glycemia in NIDDM. Diabetes Care. 17:1994;1039-1044.
14. Hansotia T., Yusta B., Drucker D.J. Activation of GLP-1 receptor signalling is coupled to inhibition of apoptosis in heterologous cell types. Diabetes. 50(Suppl. 2):2001;A350. (abstract).
15. Holst J.J. Enteroglucagon. Annu. Rev. Physiol. 59:1997;257-271.
16. Hvidberg A., Toft Nielsen M., Hilsted J., Ørskov C., Holst J.J. Effect of glucagon-like peptide 1 (proglucagon 78-107amide) on hepatic glucose production in healthy man. Metabolism. 43:1994;104-108.
17. Juhl C.B., Hollingdal M., Pørksen N., Sturis J., Jakobsen G., Schmitz O. Evidence of a substantial reduction in fasting and postprandial glycemia in type 2 diabetes after bedtime administration of a long-acting GLP-1 derivative, NN2211. Diabetes. 50(Suppl. 2):2001;A118. (abstract).
18. Knudsen L.B., Nielsen P.F., Huusfeldt P.O., Johansen N.L., Madsen K., Pedersen F.Z., Thøgersen H., Wilken M., Agersø H. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J. Med. Chem. 43:2000;1664-1669.
19. Kreymann B., Ghatei M.A., Williams G., Bloom S.R. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. II:1987;1300-1303.
20. Larsen M.O., Rolin B., Carr R.C., Svendsen O. A novel large animal model for type2 diabetes: nicotinamide and streptozotocin treated Göttingen minipigs. Diabetologia. 43(Suppl. 1):2000;A131. (abstract).
21. Larsen J., Hylleberg G., Ng K., Damsbo P. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care. 24:2001;1416-1421.
22. Mentlein R., Gallwitz B., Schmidt W.E. Dipeptidyl peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 214:1993;829-835.
23. Meyers S., Workman R., Clephane M. LY307161, a protease-protected analogue of GLP-1, with enhanced activity and time action in vivo. Diabetologia. 43(Suppl. 1):2000;A145. (abstract).
24. Miller E.R., Ullrey D.E. The pig as a model for human nutrition. Annu. Rev. Nutr. 7:1987;361-382.
25. Morales M., Lopez-Delgado M.I., Alcantara A., Luque M.A., Clemente F., Marquez L., Puente J., Vinambres C., Malaisse W.J., Villanueva-Penacarrillo M.L., Valverde I. Preserved GLP-I effects on glycogen synthase a activity and glucose metabolism in isolated hepatocytes and skeletal muscle from diabetic rats. Diabetes. 46:1997;1264-1269.
26. Nauck M.A., Kleine N., Ørskov C., Holst J.J., Wilms B., Creutzfeldt W. Normalization of fasting hyperglycemia by exogenous GLP-1 (7-36 amide) in type 2-diabetic patients. Diabetologia. 36:1993;741-744.
27. Nauck M.A., Wollschläger D., Werner J., Holst J.J., Ørskov C., Creutzfeldt W., Willms B. Effect of subcutaneous GLP-1 (7-36) amide in patients with NIDDM. Diabetologia. 39:1996;1546-1553.
28. Nauck M.A., Niederereichholz U., Ettler R., Holst J.J., Ørskov C., Ritzel R., Schmigel W.H. Glucagon-like peptide-1 inhibition of gastric-emptying outweighs its insulinotropic effects in healthy humans. Am. J. Physiol. 273:1997;E981-E988.
29. Ørskov C. Glucagon-like peptide-1, a new hormone of the enteroinsular axis. Diabetologia. 35:1978;701-711.
30. Ørskov L., Holst J.J., Møller J., Ørskov C., Moller N., Alberti K.G., Schmitz O. GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia. 39:1996;1227-1232.
31. Perea A., Vinambres C., Clemente F., Villanueva-Penacarrillo M.L., Valverde I. GLP-1 (7-36) amide: effects on glucose transport and metabolism in rat adipose tissue. Horm. Metab. Res. 29:1997;417-421.
32. Qualmann C., Nauck M., Holst J.J., Ørskov C., Creutzfeldt W. Insulinotropic effect of intravenous glucagon-like peptide (7-36 amide) in the fasting state in healthy subjects. Acta Diabetol. 32:1995;13-16.
33. Quist M.H., Hoeck U., Kreilgaard B., Madsen F., Frokjaer S. Evaluation of Göttingen minipig skin for transdermal in vitro permeation studies. Eur. J. Pharm. Sci. 11:2000;59-68.
34. Rachman J., Barrow B.A., Levy J.C., Turner R.C. Near normalization of diurnal glucose concentrations by continuous administration of GLP-1 in subjects with NIDDM. Diabetologia. 40:1997;205-211.
35. Szayna M., Doyle M.E., Betkey J.A., Holloway H.W., Spencer R.G., Greig N.H., Egan J.M. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology. 141:2000;1936-1941.
36. Toft-Nielsen M., Madsbad S., Holst J.J. Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia. Diabetologia. 41:1998;1180-1186.
37. Tumbleson M.E. Swine in Biomedical Research. vol. 1:1986;Plenum, New York.
38. Vilsboll T., Krarup T., Madsbad S., Holst J.J. No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose. Diabet. Med. 18:2001;144-149.
39. Wilken M., Larsen F.S., Juul A.-G., Jensen L.B., Ribel U. An immunoassay for the GLP-1 derivative NN2211. Diabetologia. 43(Suppl. 1):2000;A148. (abstract).
40. Willms B., Werner J., Holst J.J., Ørskov C., Creutzfeldt W., Nauck M. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous GLP-1(7-36)amide in type 2 (noninsulin-dependent) diabetic patients. J. Clin. Endocrinol. Metab. 81:1996;327-332.
41. Willms B., Idowu K., Holst J.J., Creutzfeldt W., Nauck M.A. Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients. Exp. Clin. Endocrinol. Diabetes. 106:1998;103-107.
42. Zander M., Madsbad S., Lysgaard Madsen J., Holst J.J. Effect of 6 weeks course of glucagon-like peptite-1 on glycaemic control, insulin sensitivity and β-cell function in type 2 diabetic patients: a parallel-group study. Lancet. 2002;. (in press).
43. Zar J. Biostatistical Analysis. 1984;Prentice-Hall, Upper Saddle River, NJ.